Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Mologen AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Mologen AG - Product Pipeline Review - 2014', provides an overview of the Mologen AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Mologen AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Mologen AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Mologen AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Mologen AG's pipeline products Reasons to buy - Evaluate Mologen AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Mologen AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Mologen AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Mologen AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mologen AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Mologen AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Mologen AG Snapshot 5 Mologen AG Overview 5 Key Information 5 Key Facts 5 Mologen AG - Research and Development Overview 6 Key Therapeutic Areas 6 Mologen AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Mologen AG - Pipeline Products Glance 10 Mologen AG - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Mologen AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Mologen AG - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Mologen AG - Drug Profiles 14 MGN-1703 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 MGN-1601 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 MGN-1404 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MGN-1331 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 MGN-1333 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Mologen AG - Pipeline Analysis 21 Mologen AG - Pipeline Products by Target 21 Mologen AG - Pipeline Products by Route of Administration 22 Mologen AG - Pipeline Products by Molecule Type 23 Mologen AG - Pipeline Products by Mechanism of Action 24 Mologen AG - Recent Pipeline Updates 25 Mologen AG - Dormant Projects 32 Mologen AG - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables Mologen AG, Key Information 5 Mologen AG, Key Facts 5 Mologen AG - Pipeline by Indication, 2014 7 Mologen AG - Pipeline by Stage of Development, 2014 8 Mologen AG - Monotherapy Products in Pipeline, 2014 9 Mologen AG - Phase III, 2014 10 Mologen AG - Phase II, 2014 11 Mologen AG - Phase I, 2014 12 Mologen AG - Preclinical, 2014 13 Mologen AG - Pipeline by Target, 2014 21 Mologen AG - Pipeline by Route of Administration, 2014 22 Mologen AG - Pipeline by Molecule Type, 2014 23 Mologen AG - Pipeline Products by Mechanism of Action, 2014 24 Mologen AG - Recent Pipeline Updates, 2014 25 Mologen AG - Dormant Developmental Projects,2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.